Value of Egy-Score in prediction of HCV response to sofosbuvir based therapy

Abstract

Background: Liver fibrosis (LF) develops as a result of nearly all chronic liver injuries. In order to foretell the development of the illness and monitor the effectiveness of therapy interventions, it is important to assess LF. The Egy-Score is a brand-new noninvasive score that could be utilized to predict severe LF. Objective: This research's objective is to look at whether Egy-Score can be used as a noninvasive panel of biomarkers for fibrosis for predicting the response to new hepatitis C antiviral treatments in Egyptian patients, determine if EgyScore will be affected broadly by treatment or not. Patients and methods: This study involved 100 HCV-infected patients, including chronic hepatitis and cirrhotic patients, who received new hepatitis C antiviral therapy. The patients were recruited from Kafr Elsheikh liver institute and liver clinic of Alexandria fever hospital, Egypt, and selected according to the Egyptian protocol for the treatment of hepatitis C virus. Results: Our study reported that cut-off for baseline EGY score to predict responder patients from nonresponder in all studied patients was ≤2.92, sensitivity was 77.53, Specificity 90.91, PPV was 98.6, NPV was 33.3. Cut off for baseline EGY score to predict responder patients from nonresponder in cirrhosis group was <4, sensitivity was 92.68, specificity 66.67, PPV was 92.7, NPV was 66.7. Conclusion: EgyScore showed good sensitivity, specificity, positive and negative predictive values of HCV response to sofosbuvir-based therapy, and overall accuracy for detecting different stages of hepatic fibrosis and cirrhosis in patients with chronic hepatitis C.